New Issue of PxWire: The latest in HIV prevention R&D and Delivery

As we look back on 2023, powerful cross currents confront HIV prevention and global health equity. More options than ever before could be available, but many forces threaten to undermine access to proven prevention options that exist today and the development of additional options that are still needed. Threats to PEPFAR and hate laws targeting LBGTQI+ people are just a sample.

Upstream research and development is dynamic, but robust stakeholder engagement and sustainable funding must still be secured and integrated into a people-centered research agenda. These commitments are the compass that will ultimately lead to impact in the real world. The highlights in the latest issue of PxWire provide a snapshot of key updates in Q3 of 2023 and resources to inform advocacy on these critical questions.

Read the latest issue here!

On This #GivingTuesday Support Community Leadership in HIV Prevention

Today, UNAIDS released its World AIDS Day report, Let Communities Lead. This year’s focus on community leadership is especially important to all of us at AVAC as it lies at the heart of our work for our entire 28-year history. The UNAIDS report highlights what we and our partners have raised over the years—that communities face enormous barriers, community-led responses are under-recognized, under-resourced and in so many ways, under attack.  

From our almost 30 years of experience in HIV prevention advocacy, it’s clear that working in solidarity with communities is imperative to address the root causes of inequity. Community-led responses are essential components of the comprehensive approach needed to end the epidemic.  

At AVAC, we are incredibly proud of our history and in our collaborative work in 2023 to champion civil society and community leadership in shaping local, national and global responses.

Today, as part of #GivingTuesday, a global day dedicated to giving back, we ask you to consider supporting AVAC so that we and our partners can continue to deliver the effective and impactful advocacy that is described below—and is needed now more than ever.

Your support to AVAC now will ensure that we and our partners can continue putting people and communities at the center of our work, ensuring that the global response is connected to the real needs of affected people.

Advancing bold and innovative agendas for HIV prevention.

In September, the African Women’s HIV Prevention Community Accountability Board (AWCAB) launched its  HIV Prevention Choice Manifesto  in Kampala, Uganda. The manifesto represents a historic milestone in the power of community leadership to re-frame the global discussion around community priorities. The manifesto calls for political will and financial investment to ensure access to the prevention options that women and girls in Africa say that they want. AVAC worked closely with partners to establish this coalition and catalyze its advocacy. 

Learn more.

Supporting communities to engage in the science of HIV and process of R&D. 

The Good Participatory Practice (GPP) guidelines co-developed by AVAC and UNAIDS nearly 15 years ago have become a field-wide standard for broad and inclusive stakeholder engagement in clinical trial research. At AVAC, we train trial staff on the guidelines, support their adaptation to other fields, prepare and support advocates in applying GPP in trial communities, and engage with the research community and ethics boards to maximize their use. Our new  GPP Body of Evidence, takes this a step further, offering GPP resources to advocates that demonstrate its power, show how it can be measured and replicated, and provide GPP training, tools and connection to everyone involved in the research enterprise.

Learn more.

Improving how, when and to whom prevention is delivered.

Developing—and delivering—a rich pipeline of options for HIV prevention must be guided by community priorities that define what products are needed and how they are delivered for impact. In a new opinion editorial published today in South Africa’s Bhekisisa, AVAC’s Wawira Nyagah and Mitchell Warren lay out essential lessons to ensure that a broad range of prevention options that people want and need are developed, tested and distributed equitably, at scale and with urgency. “The world cannot afford to squander another decade through slow, fragmented rollout of life-saving HIV prevention. With longer-lasting options now becoming available… the world could finally bend the curve of HIV—but only if investment and planning for delivery are as evidence-based, person-centered and innovative as research and development in new products.”

Learn more.

Supporting a robust partner network that puts prevention on national and global agendas.

Effective coordination and balanced partnerships are key to creating a policy environment, accelerating ethical product development and advocating for equitable access to emerging health solutions. AVAC partners with a global movement of advocates to bring community voices, sustained attention and greater accountability to science, policy, funding, media, health services and regulatory processes. We are proud of the skills and power-sharing and impact-oriented advocacy that has expanded and refined prevention targets, accelerated development of guidelines and reshaped policies and programs through our long-standing Advocacy Fellows program, the Coalition to build Momentum, Power, Activism, Strategy & Solidarity (COMPASS) Africa and the Coalition to Accelerate and Support Prevention Research (CASPR).

Learn more.

Fighting to keep community priorities at the center of global health.

The Coalition of Advocates for Global Health and Pandemic Preparedness is tracking the issues, keeping civil society informed, and developing tools and resources. These efforts are essential to advocacy for an integrated and holistic approach to pandemic preparedness, which depends on safeguarding equity and building on the success of the HIV response. As founding members of the coalition, we’ve been proud to fight for community priorities in the work of ACT-A, the Pandemic Fund, the Pandemic Accord, the UN High Level Meeting on PPPR, and the development of a medical countermeasures platform. AVAC published the Advocates Guide for PPPR in 2023 as a go-to resource on the issues. 

Learn more.

It is a privilege to do the work that we do. Without communities pointing the way, the HIV response will flounder, and global health will go backwards. The strength and leadership of our partners and the communities in which we work is the foundation of our hope for HIV prevention and for global health equity. We thank you for your support.

Many thanks for your partnership, solidarity and support.

New Resources & Upcoming Webinars

AVAC has a package of resources, and updates to share on cross-cutting issues facing advocates who care about global health equity and HIV prevention. From discussions on PEPFAR reauthorization, to an evolving picture on sexually transmitted infections, to the latest on the Pandemic Accord, to must-read and must-listen to updates on the state of the field and the state of access to new PrEP options, we’ve got it all. Scroll down for the latest and be sure to mark your calendars for five important webinars coming up this month!

Article: Progress Against HIV and AIDS is Fragile

Ahead of World AIDS Day, Mitchell Warren spoke with POZ Magazine for a comprehensive look at where we are in the fight against HIV/AIDS and what advocacy and scientific breakthroughs are needed in ending the epidemic. “I think a lot about the progress we’ve achieved in providing ARVs worldwide, about what the global HIV response contributed to the COVID-19 response and continues to contribute to current conversations about preparing for future pandemics. It’s remarkable… And yet that progress has not been equitable and is not yet sustainable. What we’ve achieved today could slip away so quickly…” 

add alternative text for the image

PxPulse Podcast: Inclusion of Pregnant and Lactating People in HIV Research

The newest episode of our PxPulse podcast is out now! In this episode, experts discuss why pregnant and lactating people have been excluded from HIV research in the past, and what needs to change. The podcast features Anne Drapkin Lyerly of the PHASES Project, a participant from the HPTN 084 trial in Zimbabwe, Ashley Lima of USAID, Takunda Sola of the Zimbabwe MoH AIDS/TB Unit and AVAC’s Manju Chantani-Gada and Jeanne Baron. 

Bhekisisa Podcast: The Anti-HIV Jab is Coming to South Africa

Advances in HIV prevention represent a huge opportunity to help get actual prevention choices into the hands of people. Listen to this podcast with Bhekisisa’s Mia Malan and in conversation with Mitchell Warren as they breakdown the complexity of issues in getting cabotegravir for PrEP available to those who want and need it as fast as possible. 

Webinar Recording: Boo, Syphilis is Really Back!

AVAC, NACCHO and NNPTC also hosted a webinar on the increasing rates of Syphilis rates to share learnings on how others are addressing these rising rates and the techniques clinicians are using to detect, treat, and prevent infections. 

Webinar Recording: Results from STI Landscaping Analyses in East and Southern Africa

Earlier this year, AVAC awarded seven teams funding to conduct projects in Southern and Eastern Africa to help understand the needs and evolving landscape around STI vaccines, diagnostics, and advocacy. These teams shared their findings and insights on two webinars that are not to be missed. Be sure to listen to the recordings, and to stay up to date with other STI events and resources by subscribing to our newsletter and visiting www.stiwatch.org.

Publication: Motivating Demand for the Dual Prevention Pill (DPP)

Multipurpose prevention technologies (MPTs) combining contraception with HIV prevention offer promising solutions to the challenges of adherence and uptake we’ve seen with oral PrEP. This new manuscript published in Frontiers in Reproductive Health by AVAC’s Wawira NyagahKate Segal and partners shares findings to support a demand generation approach for the DPP (Dual Prevention Pill).

Webinar Recording: Where We Are in the PEPFAR Reauthorization

The reauthorization of PEPFAR—a program that just surpassed 20 years, has been a hot button topic both in the US and abroad. Listen to Practicality Over Panic: What Happens if PEPFAR is not Reauthorized, a candid discussion hosted by the Global Health Council and Global AIDS Policy Partnership and including AVAC’s Richard Muko on where things are at. And don’t miss AVAC’s PxPulse podcast episode, PEPFAR at 20: Keeping the promise, which explores important successes of PEPFAR and why the bipartisan program has been so fundamental in ending the epidemic.

Webinar Recording: HIVR4P Preview

Ahead of the HIVR4P conference in 2024, and the 5th HIV Research for Prevention Conference, experts previewed some of the HIV prevention science to expect at these meetings. Be sure to check out the recordings on three important topics: Implementation and rolling out of CAB-LA; Insights into HIV vaccine research; and the future of bNAbs. 

Analysis: What You Need to Know About the Pandemic Accord

Negotiations around the Pandemic Accord are ongoing. Join us November 21 as we explore what’s in the Accord, what are the stakes, how can civil society engage, how will it affect our work. And to help make sense of it all, read the analysis by the Coalition of Advocates for Global Health and Pandemic Response, which is a compilation of recommendations from civil society and community organisations on the draft Negotiating Text of the WHO convention, agreement or other international instrument on pandemic prevention, preparedness, and response. 

Mark Your Calendars: Upcoming Webinars

November 15, HPTN 096: Building Equity Through Advocacy – An Integrated, Status-Neutral Approach for Ending the Epidemic Among Black Gay Men in the South 
Join The Choice Agenda and partners for a fascinating discussion about a novel, much-needed HIV prevention research study – HPTN 096. Currently in the field, the study addresses social, structural, institutional, and behavioral barriers to HIV prevention and care. Co-sponsored by PrEP in Black America and Federal AIDS Policy Partnership Research Working Group.Register here

November 15: Let’s Talk About HIV Cure Research
Join Dr. Marina Caskey of Rockefeller University and members of the REACH Community Advisory Board as they review the current state of HIV cure research. This webinar is for any person interested in learning about what makes curing HIV so challenging, the strategies being pursued, and what is happening in NYC! Register here. A follow-on webinar is scheduled for November 29

November 20: PrEP Resources Showcase 
Join AVAC and partners for a dynamic, workshop-style event exploring a digital collection of tools and resources on PrEP planning, access, trends in implementation research, and initiations to support robust access to PrEP and HIV prevention. Click here to register and learn more

November 21 to 24: Africa Health R&D Week 2023
Coalition to Accelerate & Support Prevention Research (CASPR) partners AVAC and IAVI are hosting the second Africa Health R&D Week November 21 through 24. The virtual forum will focus on the need for sustainable support for vaccine development and manufacturing in Africa, including through domestic resources mobilization. More information and registration are available here.

November 28: Spotlight on New PrEP Tools and Data: From R&D to access 
Between the recent accelerated growth in global PrEP initiations, and the introduction of new PrEP products like cabotegravir and the dapivirine vaginal ring, the field of PrEP data has never been more exciting or more complex. Join AVAC, the Medicines Patent Pool (MPP), and Unitaid to learn more about three important online PrEP resources and understand how they can support and enhance your work. 

Essential Tools for PrEP Planning and Advocacy!

More HIV prevention options are finally becoming available, including oral pills, injections and vaginal rings. Developing and delivering these options and making them actual choices for people, while also continuing to invest in the development of additional options to meet diverse needs has never been more promising or complex.  

At AVAC, we know that products don’t end pandemics unless they are delivered with equity and urgency. We created PrEPWatch.org in 2007 to serve as a go-to resource for PrEP research, and it has expanded to include toolkits, guides, data, case studies and more to support efforts to improve access to PrEP. Our data, evidence and insights, based on lessons from oral PrEP, are intended to help get the rollout of next generation right this time. 

Please join us and partners for a series of interactive sessions to guide you through these essential resources. 

November 20, PrEP Resources Showcase

Calling for collaboration: This dynamic, workshop-style showcase is the first in a series that will feature multi-media presentations to take you through key resources including a toolkit to ensure programs related to sexual and reproductive health (SRH) and HIV prevention are well designed to reach and support adolescent girls and young women; and a comprehensive database for tracking PrEP uptake, implementation research and other critical data by country. Participants will get to dive deeply into specific resources, explore how they might use these in their work, and have an opportunity to provide input on what resources are still needed.

Register here.

November 28, Spotlight on New Tools and Data: From R&D to Access

add alternative text for the image

Staying on top of the latest data on PrEP initiations, the introduction of new PrEP products and the upstream pipeline of PrEP research and development is also both essential and complex. Advocates, researchers, funders and others working in HIV prevention must understand the trends and updates to do their job effectively—but how can you navigate the vast amount of PrEP data online?

Join AVAC, Unitaid, and the Medicines Patent Pool (MPP) to learn more about three complementary online PrEP resources and understand how they can support and enhance your work: PrEPWatch.orgLong-Acting Therapeutics Patents and Licenses Database (LAPaL) and the Access to Medicines Tracker — quarterly-update on regulatory filings, regulatory approvals and product supplies of MPP-licensed generic medicines at the country level.

Register here.

Advances in HIV prevention represent a huge opportunity to help get actual prevention choices into the hands of people. We are grateful to support from the Gates Foundation for the Biomedical Prevention Implementation Collaborative (BioPIC) and from USAID and PEPFAR for the Maximizing Options to Advance Informed Choice for HIV Prevention (MOSAIC) Consortium that help make these resources possible.

We hope you’ll join us as we walk through ways you can use our resources to make this happen.

Announcing 5 New Advocacy Projects Devoted to Advancing Cure Research!

AVAC is excited to announce five new awards to accelerate advocacy for cure research.   

Five alumni from AVAC and the International AIDS Society’s renowned Advocacy-For-Cure Academy program will now receive 10-month, $10,000 fellowship awards, to identify local needs and create solutions that advance HIV cure research in their local context. These fellowships are part of the overall Advocacy-For-Cure Academy, which is a training program to prepare a generation of cure advocates to fight effectively for research that matters to the people who are most impacted by HIV. Launched in 2018 by AVAC and IAS, this program has supported 96 alumni to attend five academies. To learn more about the academy program click here

The first fellowships were issued to Cure Academy alumni in 2019 who have since developed training tools like the Series of Jojo, built partnerships between traditional healers and local researchers and promoted better understanding and translation of cure research by journalists.  

Advocates and community leaders play an important role accelerating ethical research and creating an enabling environment that allows research to thrive. These fellows are building awareness among key stakeholders about the current landscape of HIV cure research and supporting the growing movement to build a cure agenda led by countries most affected by HIV.  

Learn more about the newest cohort of fellows below. 

Josephine Achieng 

Josephine’s project uses a collaborative approach to promote HIV cure information and education for sex worker and other key population (KP) community advocates and health care workers for inclusive access to potential cures. Her project builds on former grantee Philister Adhiambo’s project to raise awareness and support among key populations. The project goal is to promote and strengthen efforts towards HIV cure research in Nairobi, Kenya. 

Charles Brown 

Charles’ HIV cure research advocacy focuses on increasing the participation of the community, policy makers and funders in HIV cure research engagement in Uganda. Charles will conduct interactive dialogues with HIV cure researchers to share information and simplify the HIV cure science while sharing opportunities to get engaged in the science. Charles will also build on advocacy efforts by past academy alumni to advance his work.  

Gastón Devisich 

Based in Buenos Aires, Argentenia, Gaston will work with regional alumni of IAS’ Research-for-a-Cure Academy and leading advocates and researchers to build The Latin American and the Caribbean HIV Cure Consortium. The Consortium will integrate and shed light on the work being conducted in the region and enhance collaborations to develop efficient, productive research and a strong advocacy agenda — producing a regional repository of HIV cure related resources in Spanish and Portuguese and a 2-year advocacy roadmap for the region. 

Doreen Moraa 

Doreen’s “”RAYS of Progress” is an HIV cure literacy project that aims to empower adolescents and young people living with HIV (AYPLHIVs) by delivering accessible information about current HIV cure research through social media platforms. She plans to meet with key stakeholders to elevate the importance of HIV cure research in Kenya. Her project, encompasses the aspect of hope, simplifying scientific concepts, encouraging involvement, and addressing stigma while showcasing the beauty of science in HIV cure research. 

Kennedy Mupeli 

Kennedy’s project aims to enhance cure literacy and advocacy skills among HIV long-term survivors  (HTLS) in four regions of Botswana by training 40 participants in basic HIV and cure science. HTLS, who have lived with HIV for decades, provide invaluable insights into the disease’s progression and resilience, underscoring the importance of their inclusion in research. From this group, four core HIV Cure Champions will receive further advocacy training in cure research, targeting both local and national levels, and will lead a National Cure Advocacy Academy to build a Botswanan agenda. 

These projects have been funded through the generous support of Aidsfund.

STIWatch Newsletter, October 2023

AVAC’s STIWatch newsletter is a curated resource on the latest in STI vaccines, diagnostics, and other prevention tools and strategies. 

STIs and HIV are commonly linked and impact similar priority populations including young people, gay, bisexual, and other men who have sex with men, transgender people, and those living with HIV. To end the AIDS epidemic, there is great need to better prevent, detect, and treat STIs as having an STI can make it easier to get HIV. However, STI research and development lags behind HIV efforts, highlighting a need for new options and programs to better address both epidemics.  

In 2022, AVAC launched an STI advocacy program to mobilize advocates to accelerate the development and equitable implementation of new STI vaccines, diagnostics, and other prevention options. Through this quarterly newsletter, we hope to share valuable information that sparks advocacy for a robust pipeline of interventions for STI prevention.  

New Resources

Visit STIwatch.org, AVAC’s updated and expanded online resource to understand and advocate for research, development and rollout of STI vaccines and diagnostics. This site features updates on the status of vaccines and diagnostics for curable STIs including:  

  • Information on chlamydia, gonorrhea, syphilis, trichomoniasis, and more. 
  • An STI clinical trials dashboard that provides information about trials focused on STI vaccines, diagnostics, and DoxyPEP. 
  • Updated graphics on the state of STI vaccines and diagnostic development. 

STI Advocacy Updates

To understand the needs and evolving landscape around STI vaccines, diagnostics, and advocacy, AVAC awarded seven teams funding to conduct projects in South and Eastern Africa. Congratulations to Nyanza Reproductive Health Society in Kenya, Lesotho Network of AIDS Service Organizations in Lesotho, JournAIDS in Malawi, HIV Survivors and Partners Network in South Africa, ACTS 101 in Uganda, Latu Human Rights Foundation in Zambia, and Pangaea Zimbabwe in Zimbabwe.  

These projects will help shed light on community needs and perceptions around STI advocacy; better understand issues and opportunities related to local STI vaccine and diagnostic research and development and identify areas to improve STI prevention efforts. Read more about the grantees and their landscaping work and join the webinar below.  

Upcoming Events

What We’re Reading

  • JournAIDS calls for increased focus on STIs in Malawi. JournAIDS Program Manager, Dingani Mithi, recently spoke about results from an STI landscaping report that identified challenges and opportunities to improve STI prevention in Malawi. As STIs can increase HIV transmission, Mithi discussed the need for increased STI screening, treatment, and education programs to reduce HIV burden. 
  • ASHM’s 2023 consensus statement on doxycycline prophylaxis (DoxyPEP). ASHM provides DoxyPEP recommendations for community and clinicians along with recommendations for research, guidelines, and policy. These recommendations are intended for gay, bisexual, and other men who have sex with men in Australia to prevent syphilis, chlamydia, and gonorrhea. Using DoxyPEP for a pre-defined period, continuing to promote STI screening, and the need for additional molecular tests to monitor AMR are all discussed within this guide.  
  • Centers for Disease Control and Prevention (CDC) Request for Comment on Guidelines for the Use of Doxycycline Post-Exposure Prophylaxis for Bacterial STIs. The CDC is requesting comments on recently released draft guidance on the use of DoxyPEP to prevent chlamydia, gonorrhea, and syphilis infections among gay, bisexual, and other men who have sex with men, and transgender women. This is an opportunity for advocates to provide feedback on guidelines that will shape clinical practices. Comments are being accepted through November 16, 2023 so share your thoughts today! 

Learn More

To learn more about AVAC’s STI Program, visit STIwatch.org and avac.org/sti. Email [email protected] for questions or additional information. And to sign up for specific updates on STIs, click here.

Paving the Road for STI Prevention Advocacy

AVAC is thrilled to announce awards to seven advocacy partners in Southern and East Africa to conduct projects on community needs for the prevention of sexually transmitted infections (STIs). Join us November 7 and November 9 as our partners present insights from these surveys, and, together, we begin to build an advocacy agenda to accelerate development of new STI vaccines, diagnostics, and other prevention tools and strategies. 

HIV is inextricably linked with other STIs. The same populations are disproportionately affected; experiences around stigma, shame, and lack of access can be remarkably similar, and STIs can increase HIV transmission and acquisition unless coupled with prevention methods like condoms and regular STI testing. Over the past decade, the global burden of STIs has increased dramatically, with the WHO estimating more than a million new cases acquired every day, while funding and other investments have lagged.  

Advocacy is needed to bring more awareness on the impact that STIs have on the health of people and communities and the need for vaccines and diagnostics to better prevent, detect, and treat infections. These advocacy projects are helping build a stronger advocacy movement to help improve funding and commitments in and around STI vaccines and diagnostics.  

The seven partners who will present their findings on the November calls include: 

ACTS101, Uganda
Team Members: Bridget Jjuuko Ndagaan, Shakira Namwanje, Arafat Kabugo

ACTS101 is engaging stakeholders across Uganda to assess and document the status of STI prevention awareness, research and development (R&D) capacity for STI prevention research, and challenges and opportunities to STI services. Learn more about ACTS101 on Twitter.

JournAIDS, Malawi
Team Members: Dingaan Mithi, Christopher Bauti, Sosten Chilumpha

JournAIDS is evaluating how best to enhance STI prevention programs in Malawi and will document critical STI advocacy opportunities. The team will work with local development partners, donors, experts, civil society, scientists, researchers and the Malawi Ministry of Health to identify priorities and next steps for STI diagnostic R&D, prevention and treatment. Learn more about JournAIDS at their website.

Lesotho Network of AIDS Service Organizations (LENASO), Lesotho
Team Members: Mamello G. Makoae, Katleho Ntheri, Tsepo Holoane, Tseliso Makoa, Nthabeleng Ntsekalle, Masheane Khasoane, Peter Raliile, Moleleki Thejane

LENASO is seeking to understand the community needs and landscape around common STIs in Lesotho in the district of Mokhotlong in Mapholaneng area where the big dam construction and mining projects are happening. LENASO is conducting interviews and focus groups for youth who are in and out of school, groups of girls and young women, and groups of males to understand the community needs and perceptions regarding STI advocacy, vaccines and diagnostics. Learn more about LENASO on Twitter @LENASO7

HIV Survivors and Partners Network, South Africa
Team Members: Mandisa Dukashe, Sakhile Xaba, Joy Neo Malesa, Khumalo Moqebelo, Phindile Nkambule

HIV Survivors and Partners Network is engaging diverse stakeholders, including government, civil society and HIV/STI implementing partners to identify community needs and perceptions around STI prevention, diagnosis and advocacy; examine challenges and opportunities related to local STI vaccine and diagnostic access; research and development needs; and opportunities to integrate existing community led programs. Learn more about the HIV Survivors and Partners Network at their website and on Facebook.

Pangaea Zimbabwe AIDS Trust (PZAT), Zimbabwe
Team Members: Imelda Mahaka, Joseph Murungu, Barbra Ncube, Cleopatra Makura, Joseph Njowa

PZAT is conducting a national situation analysis to understand the strengths, gaps, needs, opportunities, and threats in implementing a successful program focused on STI prevention and management in Zimbabwe. The situation analysis will identify existing assets in the community that could support the implementation of STI prevention and management programs; identify gaps and unmet needs that can strengthen these programs; and understand the opportunities and threats that are affecting their implementation. Learn more about PZAT at their website and on Facebook and Twitter

Nyanza Reproductive Health Society, Kenya
Team Member: Simon Odiwuor Ondiek

This project is using mixed-methods to conduct a comprehensive landscape analysis to identify existing advocacy efforts for STI vaccines and diagnostics in Kenya. By assessing the landscape, evaluating gaps and challenges, and engaging key stakeholders, the project will develop actionable recommendations and an advocacy action plan. Ultimately, the project intends to foster collaboration among stakeholders, leading to a coordinated and impactful agenda for equitable access to STI prevention tools in Kenya. In this project, Simon and NRHS collaborates closely with the National AIDS & STIs Control Program (NASCOP), Kenya’s Government agency that focuses on coordinating and overseeing the country’s efforts to combat HIV/AIDS and Sexually Transmitted Infections (STIs). Learn more about Nyanza Reproductive Health Society at their website and on Facebook and Twitter.

Latu Human Rights Foundation, Zambia
Team Member: Henry Sakala

The Latu Human Rights Foundation is examining community needs and perceptions around STI advocacy in the Lusaka Kabwe and Ndola Districts of Zambia. Findings from this landscape analysis will contribute to evidence-based decision-making, inform the development of targeted interventions, and strengthen the overall capacity of STI prevention advocacy programs in Zambia. Learn more about the Latu Human Rights Foundation on Facebook

Investing in these advocates and partner organizations and in this advocacy is an urgent priority at AVAC. Their essential work lays the foundation for drawing critical resources to STI prevention, and accelerating the development of new vaccines, diagnostics, and other prevention tools and strategies. Their work and their voices will be instrumental to strengthening STI programs and equity in sexual health. We hope you’ll join us in congratulating these partners and hearing from them in November about this important work.

Investment Trends for HIV Prevention and Cure R&D: Resource tracking reports

New Reports on HIV Prevention and Cure R&D Funding

AVAC and partners are delighted to share two new reports showing investments for HIV prevention and cure research and development (R&D) that were launched this week at the IAS 2023 Conference on HIV Science. Both reports explore a variety of factors influencing investment and detail how investment trends are changing.   

Image

In its 17th annual report, the Resource Tracking for HIV Prevention R&D Working Group, a collaboration among AVAC, IAVI and UNAIDS, documents 22 years of investment in biomedical HIV prevention R&D, including HIV vaccines, PrEP, microbicides, voluntary medical male circumcision (VMMC), treatment as prevention (TasP) or undetectable equals untransmittable (U=U), female condoms and prevention of vertical transmission (PVT).   

Key Findings and Analysis 

  • Overall, total 2021 investments (the latest data available) in HIV prevention R&D show an approximate 12% increase for HIV prevention R&D compared to 2020. Money for HIV prevention has not returned to the high-water mark seen in 2012, when total investment was US $1.31 billion, but the figures have inched back up, to $1.25 billion in 2023, from $1.09 billion in 2020.  
  • Investment in HIV vaccine research declined, but still represents a majority of all HIV prevention research. At approximately $794 million, it is 63.5% of total HIV prevention R&D.  
  • Funding for microbicides is down for the 7th year in a row, and by 20% from 2020. However, this is in part attributable to several funders shifting to consolidating the PrEP category to include all products using antiretrovirals, including topical microbicides.   
  • 2021 saw the launch of USAID’s MATRIX Consortium, supporting further research on microbicides and dual prevention options.   
  • Also launched in 2021, USAID’s MOSAIC program, focused on developing and accelerating women’s access to new HIV prevention products. MOSAIC investments, funded as part of USAID’s long-standing microbicide investments, will be recorded by the Working Group from 2022 onwards. 
  • PrEP investment saw a two-fold increase, the highest seen since the Working Group began tracking, hitting approximately $270 million in 2021.  
  • A 30% increase in VMMC in 2021 reversed a decline seen in 2020. 
  • Funding for PVT decreased from US$25 million in 2020 to US$14.3 million in 2021, the lowest level recorded by the Working Group. 
  • The ratio of public to philanthropic investment remained the same as 2020, at 81% and 12%, respectively.  
  • Global philanthropic funding levels increased 16% in 2021 to US$150 million.  
  • Though the US continues to shoulder the bulk of all funding at approximately $922 million, diversity by geography is on the up. European entities increased their investments by 40%, reaching $161 million. Diversifying the funding base is vital not only for the long-term sustainability of the field, but also to ensure that the research priorities are informed by a diversity of perspectives. 
Image

The 2021 report of the Cure Resource Tracking Group, a collaboration between AVAC and the International AIDS Society, showed an impressive 30% increase in funding for cure research.  The report also provides an analysis of the cure research agenda and the scientific questions shaping investment decisions.  

Key Findings and Analysis 

  • Total funding went from $337 million in 2020 to $439 million in 2021. This increase represents a five-fold increase since tracking began in 2012.  
  • Approximately $362 million comes from public funders, approximately $40 million comes from philanthropy. Approximately $36 million is invested by industry.  
  • Only 6% of research sponsors report participant data derived from trials conducted in African countries, even though Africa is home to 68 percent of people living with HIV. There is a growing recognition that research needs to be done among affected communities and conducted in African countries. The establishment of the HIV Cure African Acceleration Partnership (HCAAP) aims to enable stakeholder engagement.  
  • The US NIH-funded Martin Delaney Collaboratories for HIV Cure Research expanded in 2021 and now include ten collaboratories.  
  • 2021 data show sustained geographic diversity in cure R&D, with several countries joining the US to increase their funding, including Canada, Switzerland and the Netherlands. 

We hope these reports will serve as tools for advocacy and inform public policy. Funding priorities are instrumental to the decisions and commitments that allow scientific progress. All stakeholders need opportunities to understand these trends and advocate where change is needed.  

A special thank you to trial participants everywhere. Without their time and dedication, scientific advance would halt, full stop. Also thank you to the individuals who contributed data to the report.  

If your organization is a funder or recipient of HIV prevention or cure grants and we don’t know you already, please contact us at [email protected]!  

Our Take: Are the UN Declaration on PPPR and the Pandemic Accord going in the right direction?

The last few weeks have been filled with high-level negotiations among UN Member States on the way forward for global pandemic prevention, preparedness, and response (PPPR) efforts. Below, please find an analysis of the negotiated language to date in the Pandemic Accord, and the UN Declaration on PPPR, and their implications for equity in PPPR. These analyses were conducted by AVAC and partners working in collaboration to track progress toward equity in these agreements and develop an advocacy agenda for provisions in both that ensure equity in global health advances. The Declaration is an agreement that involves heads of state and potentially a role for all ministries of government. The Pandemic Accord is being negotiated by members of the WHO to strengthen PPPR.

The Pandemic Accord: A look at negotiations to date

The first draft of the WHO-led Pandemic Accord was released in May, containing edits to the zero draft from the Member States. As expected, edits from high-income countries introduced challenges to equity provisions in the text— particularly provisions aimed at ensuring that agreements to share access to data on pathogens is paired with commitments to also share the benefits developed from research using those data (termed pathogen access and benefits sharing). Other equity provisions that were challenged include intellectual property, and language on how the world should allocate vaccines, therapeutics, and diagnostics in the event of a global pandemic threat. Throughout the document, certain high-income Member States inserted caveats or wording, such as “encourage” or “as appropriate”, which would make implementation voluntary or compliance more subjective. Other phrases to weaken the agreements, such as replacing “commit to” with “recognize the importance of”, were also inserted.

Negotiations so far have resulted in weaker, alternative language to several key articles than in the so-called zero draft of the accord. These include articles on technology transfer, the Pathogen Access and Benefit Sharing (PABS) System, health workforce strengthening, and the proposed Supply Chain & Logistics Network. There are, however, some clauses that have been strengthened. Global R&D networks, laboratory networks for genomic surveillance, knowledge translation, and the harmonization of regulation to accelerate WHO pre-approval and authorization all have stronger commitments and more details than before. You can find the first draft here and a closer analysis of the changes made between the zero and first draft here.

The UN Declaration on PPPR: What’s in the Zero Draft?

The zero draft of the UN Declaration on PPPR, set to be adopted at the High-Level Meeting on September 20, was released in June.

Many provisions in the draft Declaration are positive, recognizing and affirming key points related to human rights and inclusive provisions that prioritize vulnerable and marginalized populations. The draft recognizes vaccine inequity as a vital concern, affirms key principles of equity and non-discrimination and the need to ensure adequate support for both health workers and the WHO. However, there are very few, if any, concrete targets set, leaving little to hold countries accountable. Missing from the Declaration, in particular the section on Overarching Health Related Issues, is the need for countries to prioritize and commit to building on the global responses to ongoing epidemics, including HIV/AIDS, TB, malaria, polio, other neglected disease outbreaks such as Ebola, Marburg, and cholera, and antimicrobial resistance (AMR).

This is a missed opportunity with enormous implications. It signals a troubling and serious global inability to build on existing health and community infrastructures, integrate responses, and avoid erecting isolated pillars in global health architecture. Many of the capacities needed for PPPR already exist in the response to these other health threats. They can and must be expanded and strengthened for broader pandemic preparedness. In addition, the history of the responses to HIV/AIDS, TB, and malaria have made clear that community leadership in the response and civil society engagement are essential to achieve success in PPPR. The current response to existing health threats, which through trial and error have built resilient and effective systems, should serve as the foundation for any future pandemic preparedness and response efforts. The Declaration’s silence on this issue is gravely concerning.

The Declaration’s clauses relating to agreements on pandemic-related tools and products are strong, and notably stronger than those in the first draft of the Pandemic Accord. But equity provisions, and access to those tools, could be strengthened further, by including compulsory licensing and transfer of know-how when necessary.

It’s vital for advocates to engage with these processes, and leverage their power to influence the emerging architecture in global health. Decisions being made now will have implications for years to come. And the voices of advocates are having an influence. For example, the US government’s contribution to the current draft of the UN declaration recently added specific recommendations from AVAC and partners on the inclusion of Good Participatory Practice. It’s up to all of us to make sure GPP and other provisions that ensure equity in global health are in place when the drafts become final.

You can find the Declaration zero draft here and see our analysis and the changes we call for here.

What’s Next

These negotiations are setting the direction for pandemic readiness for years to come. As discussions continue in the weeks and months ahead, it’s imperative for advocates and countries to be raising their voices and calling for language and commitments that will ensure equity in PPPR. Building on the lessons the world has learned from ongoing epidemics, and integrating the response must be a priority to ensure the tragic results of inequity in global health are not repeated, again and again.

AVAC will be sharing these analyses with our partners and governments with whom we work with. For more background, read AVAC’s Advocates Guide for PPPR. And you can take action now by sending these resources to your country’s UN representatives and other influential voices in your networks!

IAS Science 2023 Conference: What you need to know

The 12th annual conference of the International AIDS Society (IAS) on HIV science takes place July 23–26 in Brisbane, Australia, and virtually. This year’s conference will offer the latest on vaccine and cure science, research updates on broadly neutralizing antibodies, important discussions on trial design in the era of PrEP, the potential of community-led models of care and the importance of integrating services for HIV and sexual and reproductive health (SRH). AVAC and partners will be there! Read on for an overview.

Just ahead of the conference, UNAIDS released their annual state of the epidemic report, The Path that Ends AIDS. The report charts a path that can end AIDS, and documents important progress, but challenges remain. Among them, global resources for HIV are marking another year of decline. With anti-LGTBQIA+ legal actions increasing in the US and in several African countries and reduced resources, efforts to end the epidemic will fail. See AVAC’s new graphic on the issue.

title card with presentation info

IAS Resources

  • Use AVAC’s Roadmap to find sessions where prevention, pandemic preparedness and the larger issues of global health equity are in the spotlight. You can download it as a sortable spreadsheet or PDF.
  • Follow events in real time, AVAC will offer comments and updates on Twitter, and our friends at NAM/AIDSMAP will be reporting throughout the conference. Join the conversation using the conference hashtag #IAS2023.

Satellites, Sessions and Panels Featuring AVAC and Partners

All times listed are local in Brisbane, Australia. Click for a time zone converter.

Sunday, July 23

Tuesday, July 25

Wednesday, July 26

Poster Presentations

  • No Data No More: A tool to end the exclusion of trans and gender-diverse people in HIV research
  • Raising New Voices in HIV Cure Research: A review of an advocacy-for-cure academy and grant program
  • The Value of Measuring Outcomes of HIV Advocacy: Utilising a novel and participatory approach for advocacy evaluation
  • HIV Prevention Research & Development Investments 2001-2021: Shifting investment priorities fund innovation in a challenging global health landscape
  • Revolution of Transgender Health Programming: The role of transgender activists in Health programming for Malawi

While many will be gathering in Australia for the IAS conference, the 27th International Society for Sexually Transmitted Diseases Research (ISSTDR) is happening in Chicago at the same time – and AVAC will be there, too. Stay tuned for an update later this week for AVAC’s STI Roadmap and dedicated STI conference page. Advocates, implementers and researchers in both fields have much work to do together.